Want to see SCNX full AI Analyst Report?
SCNX Stock Chart & Stats
$0.55
-$0.13(-2.47%)
At close: 4:00 PM EST
$0.55
-$0.13(-2.47%)
Day’s Range― - ―
52-Week Range$0.24 - $2.60
Previous CloseN/A
Volume1.53K
Average Volume (3M)4.08M
Market Cap
$13.53M
Enterprise Value-$3.53B
Total Cash (Recent Filing)$3.54B
Total Debt (Recent Filing)$10.00M
Price to Earnings (P/E)―
Beta3.25
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding40,630,814
10 Day Avg. Volume11,411,402
30 Day Avg. Volume4,082,790
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.12
Price to Sales (P/S)181.35
P/FCF Ratio>-0.01
Enterprise Value/Market Cap-260.66
Enterprise Value/Revenue-7.38K
Enterprise Value/Gross Profit35.69K
Enterprise Value/Ebitda89.40
Forecast
1Y Price Target
$1.50Price Target Upside172.73% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage On Balance SheetVery low recent leverage meaningfully reduces near-term solvency risk and preserves the company’s ability to access additional financing or support commercialization spending. This structural balance-sheet strength lengthens runway versus highly levered peers despite operating losses.
TTM Revenue Jump With High Gross MarginA sharp trailing‑12‑month revenue increase combined with high gross margins suggests product or commercial traction and scalable unit economics. If sustained, this supports margin expansion as fixed costs are leveraged and improves the odds of transitioning toward operating profitability.
Experienced Interim CFO & Management ContinuityInternal appointment of a seasoned pharma executive who has overseen finance since May 2025 provides continuity and credible oversight during transition. Durable management strength reduces execution risk on commercialization and financing plans over the next several quarters.
Bears Say
Material Cash BurnConsistently negative operating and free cash flow indicate the business consumes cash to operate and commercialize products. This structural cash burn forces repeated external financing, constrains discretionary R&D/commercial spending, and increases dilution or creditor dependence over months.
Deep Operating Losses And Negative MarginsLarge, persistent losses and negative margins show the company has yet to convert revenue into sustainable profits. This undermines internal funding ability, prolongs reliance on capital markets, and pressures long‑term returns unless structural cost or revenue improvements are realized.
Restrictive Structured Financing TermsThe recent secured financing improves liquidity but imposes tight covenants, lender security interests and triggers that can accelerate repayment or raise costs. These structural constraints reduce operational flexibility and raise the risk of forced deleveraging or asset encumbrance if targets slip.
Scienture Holdings News
SCNX FAQ
What was Scienture Holdings’s price range in the past 12 months?
Scienture Holdings lowest stock price was $0.24 and its highest was $2.60 in the past 12 months.
What is Scienture Holdings’s market cap?
Scienture Holdings’s market cap is $13.53M.
When is Scienture Holdings’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Scienture Holdings’s earnings last quarter?
Currently, no data Available
Is Scienture Holdings overvalued?
According to Wall Street analysts Scienture Holdings’s price is currently Undervalued.
Does Scienture Holdings pay dividends?
Scienture Holdings pays a Notavailable dividend of $1.5 which represents an annual dividend yield of N/A. See more information on Scienture Holdings dividends here
What is Scienture Holdings’s EPS estimate?
Scienture Holdings’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Scienture Holdings have?
Scienture Holdings has 40,630,814 shares outstanding.
What happened to Scienture Holdings’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Scienture Holdings?
Currently, no hedge funds are holding shares in SCNX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Scienture Holdings
As a health services IT enterprise, TRxADE HEALTH, Inc. manages an online platform designed to facilitate transactions between licensed pharmaceutical wholesalers and healthcare providers. This digital marketplace enables wholesalers to distribute a broad spectrum of products and services, encompassing branded and generic drugs as well as other non-pharmaceutical items. Customers for these offerings span government organizations, hospitals, medical clinics, and independent pharmacies. The firm's corporate base is situated in Tampa, Florida.
SCNX Stock 12 Month Forecast
Average Price Target
$1.50
▲(172.73% Upside)
Technical Analysis
Ownership Overview
16.82% Insiders
1.70% Mutual Funds
<0.01% Other Institutional Investors
80.47% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---